Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1441-1446

  Sato, Aya ^a   Nagase, Hiroki ^b   Obinata, Daisuke ^a   Fujiwara, Kyoko ^a   Fukuda, Noboru ^a   Soma, Masayoshi ^a   Yamaguchi, Kenya ^a   Kawata, Nozomu ^a   Takahashi, Satoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Matrix metalloproteinase; Pyrrole imidazole polyamide; Renal cell carcinoma

Indexed keywords

GELATINASE B; IMIDAZOLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MESSENGER RNA; POLYAMIDE; PYRROLE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL INVASION; CELL PROLIFERATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL ADHESION; CELL DIVISION; CELL PROLIFERATION; FEMALE; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NYLONS; PROGNOSIS; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84885066607     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2073     Document Type: Article

References (25)

1. Srinivasan R, Armstrong AJ, Dahut W, et al: Anti-angiogenic therapy in renal cell cancer. BJU Int 99: 1296-1300, 2007.
2. Board RE, Thistlethwaite FC and Hawkins RE: Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 33: 1-8, 2007.
3. Figlin RA: Anti-angiogenic therapy in renal cell carcinoma: alone, in combination, or sequentially. Clin Adv Hematol Oncol 7: 662-665, 2009.
4. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
5. Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41: 271-290, 2011.
6. Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20: 161-168, 2010.
7. Lukaszewicz-Zajac M, Mroczko B and Szmitkowski M: Gastric cancer - the role of matrix metalloproteinases in tumor progression. Clin Chim Acta 412: 1725-1730, 2011.
8. Cho NH, Shim HS, Rha SY, et al: Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44: 560-566, 2003.
9. Awakura Y, Ito N, Nakamura E, et al: Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett 241: 59-63, 2006.
10. Zhang X, Yamashita M, Uetsuki H, et al: Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 9: 509-514, 2002.
11. Sherief MH, Low SH, Miura M, et al: Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 169: 1530-1534, 2003.
12. Kallakury BV, Karikehalli S, Haholu A, et al: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
13. Kawata N, Nagane Y, Hirakata H, et al: Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 69: 1049-1053, 2007.
14. Kawata N, Nagane Y, Igarashi T, et al: Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. Urology 68: 523-527, 2006.
15. Lai YM, Fukuda N, Ueno T, et al: Synthetic pyrrole-imidazole polyamide inhibits expression of the human transforming growth factor-beta1 gene. J Pharmacol Exp Ther 315: 571-575, 2005.
16. Kageyama Y, Sugiyama H, Ayame H, et al: Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol 45: 317-324, 2006.
17. Matsuda H, Fukuda N, Ueno T, et al: Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-beta1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol 17: 422-432, 2006.
18. Minoshima M, Sasaki S, Fujimoto J, et al: Synthesis and biological properties of pyrrole-imidazole polyamide conjugates. Nucleic Acids Symp Ser (Oxf), pp35-36, 2007.
19. Wang X, Nagase H, Watanabe T, et al: Inhibition of MMP-9 transcription and suppression of tumor metastasis by pyrrole-imidazole polyamide. Cancer Sci 101: 758-766, 2010.
20. Chakravarty D, Roy SS, Babu CR, et al: Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 17: 2250-2259, 2011.
21. Stellas D, El Hamidieh A and Patsavoudi E: Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11: 51, 2010.
22. Yan L, Kumagai SG, McGuire MH, et al: Protease activity and invasion of matrigel by the osteosarcoma-derived OSPR cell line. Biochem Soc Trans 22: S18, 1994.
23. Hall DMS and Brooks SA: In vitro invasion assay using matrigel(R). Methods Mol Med 58: 61-70, 2001.
24. Deryugina EI, Luo GX, Reisfeld RA, et al: Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17: 3201-3210, 1997.
25. Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36, 2011.